HRP20201995T1 - Toplinski-sterilizirani pripravak koji sadrži hitozan i postupak njegove pripreme - Google Patents
Toplinski-sterilizirani pripravak koji sadrži hitozan i postupak njegove pripreme Download PDFInfo
- Publication number
- HRP20201995T1 HRP20201995T1 HRP20201995TT HRP20201995T HRP20201995T1 HR P20201995 T1 HRP20201995 T1 HR P20201995T1 HR P20201995T T HRP20201995T T HR P20201995TT HR P20201995 T HRP20201995 T HR P20201995T HR P20201995 T1 HRP20201995 T1 HR P20201995T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- chitosan
- glycerol
- aqueous
- preparation according
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title claims 15
- 238000000034 method Methods 0.000 title claims 11
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 21
- 239000002253 acid Substances 0.000 claims 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 230000006196 deacetylation Effects 0.000 claims 3
- 238000003381 deacetylation reaction Methods 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 229940074404 sodium succinate Drugs 0.000 claims 3
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims 2
- 239000004373 Pullulan Substances 0.000 claims 2
- 229920001218 Pullulan Polymers 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000010241 potassium sorbate Nutrition 0.000 claims 2
- 239000004302 potassium sorbate Substances 0.000 claims 2
- 229940069338 potassium sorbate Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 235000019423 pullulan Nutrition 0.000 claims 2
- 241000222519 Agaricus bisporus Species 0.000 claims 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010015946 Eye irritation Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 231100000013 eye irritation Toxicity 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/05—Alcohols; Metal alcoholates
- C08K5/053—Polyhydroxylic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/719—Pullulans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
- C08L3/12—Amylose; Amylopectin; Degradation products thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2201/00—Properties
- C08L2201/10—Transparent films; Clear coatings; Transparent materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2201/00—Properties
- C08L2201/54—Aqueous solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (20)
1. Postupak za pripremu toplinski-steriliziranog vodenog pripravka koji sadrži otopljeni hitozan i glicerol, pri čemu je navedena pripravak bistra i viskozna otopina, pri pH između 6 i 7.5, naznačen time da navedeni postupak obuhvaća sljedeće korake:
(i) Otapanje hitozana koji ima prosječnu molekulsku masu u opsegu od oko 10 kDa do oko 250 kDa i stupanj deacetilacije veći od 60% u vodenoj otopini slabe kiseline koja sadrži karboksilnu skupinu, pri čemu je molarni odnos između karboksilne skupine (-COOH) spomenute slabe kiseline i amino skupine (-NH2) spomenutog hitozana između 1:0.9 i 1:1.1, kao što je oko 1:1 ili 1:1.05;
(ii) Dodavanje glicerola;
(iii) Podešavanje pH na pH između 6 i 7.5 dodavanjem vodene otopine slabe baze; i
(iv) Sterilizacija parom;
čime nastaje toplinski-sterilizirani pripravak koji sadrži otopljeni hitozan i glicerol, koja je bistra i viskozna otopina pri pH koji je između 6 i 7.5.
2. Postupak prema patentnom zahtjevu 1, naznačen time da je spomenuta slaba kiselina mliječna kiselina.
3. Postupak prema patentnom zahtjevu 1 ili 2, naznačen time da je slaba baza izabrana između natrijevog sukcinata i kalijevog sorbata.
4. Postupak prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time da je:
- u koraku (i), spomenuti hitozan prisutan u koncentraciji između 0.05 i 3% (w/w), a spomenuta slaba kiselina je mliječna kiselina prisutna u koncentraciji između 0.12 i 0.22% (w/w),
- u koraku (ii), spomenuti glicerol prisutan u koncentraciji između 0.4 i 1% (w/w), i
- u koraku (iii), spomenuta slaba baza natrijev sukcinat prisutan u koncentraciji između 1.0 i 1.7% (w/w).
5. Postupak prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačen time da spomenuti hitozan iz koraka (i) ima prosječnu molekulsku težinu (MT) u rasponu od oko 150 do oko 180 kDa i stupanj deacetilacije (DD) obuhvaćen između 60 % (mol) i 75% (mol).
6. Postupak prema bilo kojem od patentnih zahtjeva od 1 do 5, naznačen time da je navedeni hitozan iz koraka (i) hitozan u amino-obliku.
7. Postupak prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time da je spomenuti hitozan iz koraka (i) hitozan gljivičnog porijekla, naročito od Agaricus bisporus.
8. Postupak prema bilo kojem od patentnih zahtjeva od 1 do 7, naznačen time da je hitozan otopljen u koraku (i) u vodenoj otopini slabe kiseline koja sadrži otopljeni pululan.
9. Toplinski-sterilizirani vodeni pripravak koja sadrži otopljeni hitozan i glicerol, naznačen time da se može dobiti postupkom prema bilo kojem od patentnih zahtjeva od 1 do 8.
10. Pripravak prema patentnom zahtjevu 9, naznačen time da spomenuti pripravak ima viskoznost između 10 i 500 mPa.s.
11. Pripravak prema bilo kojem od patentnih zahtjeva od 9 do 10, naznačen time da spomenuti pripravak ima osmozitet između 150 i 350 mOsm/kg.
12. Farmaceutski pripravak, naznačen time da sadrži pripravak prema bilo kojem od patentnih zahtjeva od 9 do 11 i barem jedan farmaceutski prihvatljiv nosač, diluent ili njegov ekscipijent.
13. Toplinski-sterilizirani farmaceutski vodeni pripravak koji sadrži vodeno-netopljivi hitozan otopljen u slaboj kiselini koja sadrži karboksilnu skupinu i glicerol, naznačen time da spomenuti hitozan ima prosječnu molekulsku masu u rasponu od oko 150 do oko 180 kDa i stupanj deacetilacije (DD) između 60% (mol) i 75% (mol).
14. Vodeni pripravak prema patentnom zahtjevu 13, naznačen time da je spomenuta slaba kiselina mliječna kiselina, glicerol je prisutan u koncentraciji u rasponu od oko 0.2 do oko 1% (w/w), računato na bazi ukupnog pripravka, a pripravak je oftalmološki pripravak.
15. Pripravak prema bilo kojem od patentnih zahtjeva od 12 do 14, naznačen time da spomenuti pripravak ima viskozitet između 10 i 500 mPa.s., osmozitet između 150 i 350 mOsm/kg, i pokazuje ne-Njutnovsko reološko ponašanje, antimikrobijalnu aktivnost i/ili anti-lipaznu aktivnost.
16. Pripravak prema bilo kojem od patentnih zahtjeva od 13 do 15, naznačen time da je slaba baza izabrana od natrijevog sukcinata i kalijevog sorbata.
17. Pripravak prema bilo kojem od patentnih zahtjeva od 13 do 16, naznačen time da dalje sadrži pululan.
18. Pripravak prema bilo kojem od patentnih zahtjeva od 15 do 17, naznačen time da je za upotrebu u prevenciji i/ili liječenju sindroma suhog oka, naročito suhog oka sa blefaritisom, iritacije oka izazvane uvjetima okoline ili kontaktnim lećama, keratokonjunktivitisa sicca, Sjogrenovog sindroma bakterijskih infekcija na površini oka ili srodnim prednjim strukturama oka.
19. Pripravak prema bilo kojem od patentnih zahtjeva od 9 do 18, naznačen time da je za upotrebu kao lijek.
20. Pripravak prema bilo kojem od patentnih zahtjeva od 9 do 18, naznačen time da je za upotrebu u prevenciji i/ili liječenju artritične bolesti ili poremećaja odabranog između osteoartritisa i psorijatičnog artritisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073246 WO2016066195A1 (en) | 2014-10-29 | 2014-10-29 | Heat-sterilized formulation comprising chitosan and process of preparation thereof |
| EP15798206.7A EP3212166B1 (en) | 2014-10-29 | 2015-10-28 | Heat-sterilized formulation comprising chitosan and process of preparation thereof |
| PCT/IB2015/058300 WO2016067210A1 (en) | 2014-10-29 | 2015-10-28 | Heat-sterilized formulation comprising chitosan and process of preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201995T1 true HRP20201995T1 (hr) | 2021-02-05 |
Family
ID=51842529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201995TT HRP20201995T1 (hr) | 2014-10-29 | 2020-12-14 | Toplinski-sterilizirani pripravak koji sadrži hitozan i postupak njegove pripreme |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10493155B2 (hr) |
| EP (1) | EP3212166B1 (hr) |
| JP (1) | JP6814133B2 (hr) |
| KR (1) | KR102421423B1 (hr) |
| CN (1) | CN107075174B (hr) |
| CA (1) | CA2965447C (hr) |
| CO (1) | CO2017003840A2 (hr) |
| DK (1) | DK3212166T3 (hr) |
| ES (1) | ES2857273T3 (hr) |
| HR (1) | HRP20201995T1 (hr) |
| HU (1) | HUE053432T2 (hr) |
| MX (1) | MX2017004760A (hr) |
| PT (1) | PT3212166T (hr) |
| RS (1) | RS61214B1 (hr) |
| RU (1) | RU2712271C2 (hr) |
| SI (1) | SI3212166T1 (hr) |
| WO (2) | WO2016066195A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10576099B2 (en) | 2016-10-21 | 2020-03-03 | Covidien Lp | Injectable scaffold for treatment of intracranial aneurysms and related technology |
| US11452783B2 (en) * | 2017-02-14 | 2022-09-27 | Gi Supply | Tissue stain and use thereof |
| WO2020208418A1 (en) * | 2019-04-12 | 2020-10-15 | Azura Ophthalmics Ltd. | Compositions and methods for the treatment of contact lens discomfort |
| JP7453036B2 (ja) | 2020-03-30 | 2024-03-19 | 株式会社ナリス化粧品 | 皮膚外用剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659700A (en) * | 1984-03-02 | 1987-04-21 | Johnson & Johnson Products, Inc. | Chitosan-glycerol-water gel |
| JPS6462302A (en) * | 1987-09-01 | 1989-03-08 | Nippon Suisan Kaisha Ltd | Water-soluble chitosan salt and production thereof |
| JPH06107551A (ja) * | 1992-09-30 | 1994-04-19 | Hisamitsu Pharmaceut Co Inc | 関節症治療剤 |
| JPH07118304A (ja) * | 1993-10-27 | 1995-05-09 | Asahi Glass Co Ltd | キトサン水溶液 |
| US5420197A (en) * | 1994-01-13 | 1995-05-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| AU6742696A (en) | 1995-08-17 | 1997-03-12 | Ciba-Geigy Ag | Stabilized chitin derivative compounds |
| SI1128809T1 (en) * | 1998-11-20 | 2005-06-30 | Laboratoire Medidom S.A. | Aqueous ophthalmic formulations comprising chitosan |
| JP5116129B2 (ja) * | 2000-09-01 | 2013-01-09 | 日本水産株式会社 | 中性付近のキトサン水溶液の製造法 |
| US20020119949A1 (en) * | 2001-02-26 | 2002-08-29 | Asa Hellman | Prophylactic teat treatment |
| EP1550674B1 (en) * | 2002-10-08 | 2016-12-07 | Ricom Corporation | Chitosan-containing polysaccharide, process for producing the same and use thereof |
| DE602005016030D1 (de) * | 2005-12-23 | 2009-09-24 | Medidom Lab | Duroplastische neutralisierte chitosan-zusammensetzung zur bildung eines hydrogels, lyophilisats, und herstellungsverfahren dafür |
| US9034348B2 (en) * | 2006-12-11 | 2015-05-19 | Chi2Gel Ltd. | Injectable chitosan mixtures forming hydrogels |
| US20090142292A1 (en) * | 2007-12-03 | 2009-06-04 | Blackwell Richard I | Method For The Mitigation of Symptoms of Dry Eye |
-
2014
- 2014-10-29 WO PCT/EP2014/073246 patent/WO2016066195A1/en active Application Filing
-
2015
- 2015-10-28 KR KR1020177009821A patent/KR102421423B1/ko active IP Right Grant
- 2015-10-28 CN CN201580055822.2A patent/CN107075174B/zh active Active
- 2015-10-28 PT PT157982067T patent/PT3212166T/pt unknown
- 2015-10-28 RU RU2017118261A patent/RU2712271C2/ru active
- 2015-10-28 US US15/522,789 patent/US10493155B2/en active Active
- 2015-10-28 MX MX2017004760A patent/MX2017004760A/es unknown
- 2015-10-28 EP EP15798206.7A patent/EP3212166B1/en active Active
- 2015-10-28 ES ES15798206T patent/ES2857273T3/es active Active
- 2015-10-28 DK DK15798206.7T patent/DK3212166T3/da active
- 2015-10-28 CA CA2965447A patent/CA2965447C/en active Active
- 2015-10-28 SI SI201531447T patent/SI3212166T1/sl unknown
- 2015-10-28 JP JP2017515799A patent/JP6814133B2/ja active Active
- 2015-10-28 HU HUE15798206A patent/HUE053432T2/hu unknown
- 2015-10-28 RS RS20201504A patent/RS61214B1/sr unknown
- 2015-10-28 WO PCT/IB2015/058300 patent/WO2016067210A1/en active Application Filing
-
2017
- 2017-04-20 CO CONC2017/0003840A patent/CO2017003840A2/es unknown
-
2020
- 2020-12-14 HR HRP20201995TT patent/HRP20201995T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107075174B (zh) | 2021-03-30 |
| CN107075174A (zh) | 2017-08-18 |
| MX2017004760A (es) | 2017-07-26 |
| DK3212166T3 (da) | 2021-02-22 |
| PT3212166T (pt) | 2021-02-09 |
| US20170312364A1 (en) | 2017-11-02 |
| CA2965447A1 (en) | 2016-05-06 |
| HUE053432T2 (hu) | 2021-07-28 |
| CA2965447C (en) | 2022-05-31 |
| BR112017008353A2 (pt) | 2017-12-19 |
| KR20170076659A (ko) | 2017-07-04 |
| KR102421423B1 (ko) | 2022-07-15 |
| CO2017003840A2 (es) | 2017-04-28 |
| ES2857273T3 (es) | 2021-09-28 |
| RS61214B1 (sr) | 2021-01-29 |
| RU2017118261A (ru) | 2018-11-29 |
| JP2017533186A (ja) | 2017-11-09 |
| RU2017118261A3 (hr) | 2019-04-25 |
| RU2712271C2 (ru) | 2020-01-28 |
| WO2016067210A1 (en) | 2016-05-06 |
| WO2016066195A1 (en) | 2016-05-06 |
| EP3212166A1 (en) | 2017-09-06 |
| US10493155B2 (en) | 2019-12-03 |
| EP3212166B1 (en) | 2020-12-02 |
| JP6814133B2 (ja) | 2021-01-13 |
| SI3212166T1 (sl) | 2021-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201995T1 (hr) | Toplinski-sterilizirani pripravak koji sadrži hitozan i postupak njegove pripreme | |
| US20170105934A1 (en) | Aqueous ophthalmic composition | |
| JP6832390B2 (ja) | 水性液剤 | |
| PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| JP2010540619A5 (hr) | ||
| JP2017533186A5 (hr) | ||
| SI2961481T1 (en) | Topical antimicrobial dermatological composition | |
| JP5518608B2 (ja) | 粘膜適用液状組成物 | |
| JP2024010178A (ja) | 眼科組成物 | |
| CL2020001156A1 (es) | Formulaciones de liberación prolongada para aplicaciones intra-articulares. | |
| TW201542241A (zh) | 兩性離子性軟式隱形眼鏡用眼科用組成物 | |
| RU2724955C2 (ru) | Офтальмологическая композиция, содержащая липоевую кислоту и мукомиметический полимер | |
| JP5246182B2 (ja) | 点眼剤、防腐剤及び防腐力向上剤 | |
| WO2014204357A3 (ru) | Лекарственное средство для лечения кератоконуса | |
| AR115049A1 (es) | Carboxialquil quitosano | |
| JP7191515B2 (ja) | 眼科組成物 | |
| TWI626060B (zh) | 兩性離子性軟式隱形眼鏡用眼科用組成物 | |
| JP2012224872A (ja) | 水溶性高分子増粘剤を含有する組成物の安定化剤 | |
| AR113822A1 (es) | Formulaciones de liberación extendida para aplicaciones intra-articulares | |
| BR112017008353B1 (pt) | Formulação termoesterilizada compreendendo quitosana e processo de preparação da mesma | |
| TH142795A (th) | วิธีการผลิตสูตรส่วนผสมยาด็อกซี่ซัยคลิน (DoxycyclineHyclate)สำหรับละลายน้ำ |